UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (931) 931
Newspaper Article (49) 49
Web Resource (16) 16
Book / eBook (8) 8
Book Chapter (4) 4
Publication (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (302) 302
life sciences & biomedicine (300) 300
humans (261) 261
hematology (211) 211
oncology (174) 174
female (153) 153
male (151) 151
aged (144) 144
middle aged (144) 144
adult (98) 98
leukemia (89) 89
treatment outcome (82) 82
aged, 80 and over (81) 81
myelodysplastic syndromes (74) 74
prognosis (72) 72
myelodysplastic syndromes - drug therapy (65) 65
abridged index medicus (64) 64
myelodysplastic syndromes - genetics (59) 59
risk factors (56) 56
cancer (50) 50
mutation (49) 49
patients (48) 48
chemotherapy (43) 43
bone marrow (40) 40
hematology, oncology and palliative medicine (39) 39
myelodysplastic syndromes - diagnosis (38) 38
care and treatment (37) 37
myelodysplastic syndrome (37) 37
myelodysplastic syndromes - pathology (37) 37
young adult (36) 36
leukemia, myeloid, acute - drug therapy (34) 34
myelodysplastic syndromes - therapy (34) 34
mds (33) 33
acute myeloid leukemia (32) 32
myelodysplastic syndromes - mortality (32) 32
adolescent (31) 31
antineoplastic agents - therapeutic use (31) 31
hemic and lymphatic diseases (31) 31
research (31) 31
remission induction (30) 30
retrospective studies (29) 29
leukemia, myeloid, acute - genetics (28) 28
survival analysis (28) 28
antineoplastic combined chemotherapy protocols - therapeutic use (27) 27
survival rate (27) 27
leukemia, myeloid, acute - mortality (26) 26
transplantation (21) 21
antimetabolites, antineoplastic - therapeutic use (20) 20
azacitidine - analogs & derivatives (20) 20
disease progression (20) 20
thalidomide - analogs & derivatives (20) 20
azacitidine - therapeutic use (19) 19
cancer therapies (19) 19
cytarabine - administration & dosage (19) 19
cytogenetics (19) 19
disease-free survival (19) 19
analysis (18) 18
decitabine (18) 18
leukemia, myeloid, acute - pathology (18) 18
medical research (18) 18
myeloid neoplasia (18) 18
survival (17) 17
thalidomide - therapeutic use (17) 17
azacitidine (16) 16
chromosome aberrations (16) 16
clinical trials (16) 16
cohort studies (16) 16
genetic aspects (16) 16
hematopoietic stem cell transplantation (16) 16
patient outcomes (16) 16
age factors (15) 15
chromosome deletion (15) 15
follow-up studies (15) 15
leukemia, myeloid, acute - diagnosis (15) 15
polymorphism, single nucleotide (15) 15
recurrence (15) 15
animals (14) 14
drug administration schedule (14) 14
hematopoietic stem cells (14) 14
hospitals (14) 14
karyotyping (14) 14
leukemia, myeloid, acute - therapy (14) 14
time factors (14) 14
aml (13) 13
antineoplastic combined chemotherapy protocols - adverse effects (13) 13
azacitidine - administration & dosage (13) 13
lenalidomide (13) 13
medical prognosis (13) 13
myelodysplastic syndromes - classification (13) 13
myeloproliferative disorders - genetics (13) 13
united states (13) 13
blood (12) 12
clinical trials and observations (12) 12
clinical trials as topic (12) 12
kaplan-meier estimate (12) 12
myelodysplastic syndromes - epidemiology (12) 12
treatment (12) 12
blood transfusion (11) 11
disorders (11) 11
health aspects (11) 11
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Drugs, ISSN 0012-6667, 2005, Volume 65, Issue 13, pp. 1790 - 1791
...] A Viewpoint by Mikkael A. Sekeres (and which would have called for maintaining a Department of Hematology and Medical response for 8, rather than 4, weeks... 
Azacitidine | Adis Drug Profiles | Myelodysplastic syndromes | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Pharmacology & Pharmacy | Toxicology | Life Sciences & Biomedicine | Science & Technology
Journal Article
2017, Fifth edition., ISBN 9781119196204, 1299
The fifth edition of the only comprehensive text dealing exclusively with rare or infrequently encountered malignancies in adults and children is an essential... 
Rare Diseases | Neoplasms | Tumors | Rare diseases | Cancer
Book
02/2020, The MIT Press, ISBN 0262043726, 1
.... The two of you are in it together. In When Blood Breaks Down, Mikkael Sekeres, a leading cancer specialist, takes readers on the journey that patient and doctor travel together... 
eBook
2020, ISBN 0262043726, 325
A leading cancer specialist tells the compelling stories of three adult leukemia patients and their treatments, the disease itself, and the drugs developed to... 
eBook
Cancer, ISSN 0008-543X, 05/2017, Volume 123, Issue 6, pp. 994 - 1002
Journal Article
Cancer, ISSN 0008-543X, 08/2015, Volume 121, Issue 16, pp. 2678 - 2680
Older adults with acute myeloid leukemia should be better prepared for the difficult realities of their disease, and clinicians should adjust their optimism... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Female | Male | Terminal Care | Patient Acceptance of Health Care | Humans | Leukemia, Myeloid, Acute - therapy | Index Medicus | Abridged Index Medicus
Journal Article
British journal of haematology, ISSN 0007-1048, 09/2017, Volume 178, Issue 6, pp. 906 - 913
Romiplostim can improve platelet counts in about 50% of patients with low- or intermediate 1-risk (lower risk) myelodysplastic syndromes (MDS) and... 
thrombopoietin receptor agonist | romiplostim | thrombocytopenia | platelets | myelodysplastic syndromes | Life Sciences & Biomedicine | Hematology | Science & Technology | Follow-Up Studies | Recombinant Fusion Proteins - adverse effects | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Male | Thrombopoietin - therapeutic use | Myelodysplastic Syndromes - blood | Thrombopoietin - administration & dosage | Receptors, Fc - therapeutic use | Thrombocytopenia - drug therapy | Aged, 80 and over | Adult | Female | Leukemia, Myeloid, Acute - chemically induced | Myelodysplastic Syndromes - drug therapy | Recombinant Fusion Proteins - administration & dosage | Hematologic Agents - adverse effects | Drug Administration Schedule | Hematologic Agents - therapeutic use | Treatment Outcome | Disease Progression | Thrombocytopenia - blood | Receptors, Thrombopoietin - agonists | Platelet Count | Thrombopoietin - adverse effects | Receptors, Fc - administration & dosage | Aged | Hematologic Agents - administration & dosage | Hemorrhage - chemically induced | Medicine, Experimental | Medical research | Leukemia | Myelodysplastic syndromes | Thrombocytopenia | Effectiveness | Toxicity | Disorders | Risk | Safety | Platelets | Patients | Myelodysplastic syndrome | Bleeding | Index Medicus | Haematological Malignancy | Research Paper
Journal Article
American journal of hematology, ISSN 0361-8609, 11/2018, Volume 93, Issue 11, pp. 1301 - 1310
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2012, Volume 30, Issue 12, pp. 1343 - 1349
Journal Article